{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "Explicitly stated as the relevance rule and matches the guideline for relevance filter using client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase II",
          "Phase 3",
          "Phase III",
          "meta-analysis",
          "real-world data",
          "patient reported outcomes",
          "PROs",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "Rule is based on specific trial phases, data types, and treatment keywords; exclusion added to ensure mutual exclusivity with 'INTERNAL' priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored",
          "Ardelyx"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "Direct sponsorship keyword; mutually exclusive from other priorities by exclusion in 'High'."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts and all High priority concepts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "Phase I",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints",
          "general study"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "patient reported outcomes",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "Rule is based on trial phase, study type, and outcomes; exclusions ensure mutual exclusivity with 'Internal' and 'High' priorities."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE Ardelyx sponsored abstracts and all High/Medium priority concepts",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [],
        "contextual_concepts": [
          "mention of indication only",
          "no trial data",
          "no study outcomes",
          "no endpoints",
          "no treatment data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "patient reported outcomes",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "Phase 1",
        "Phase I",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints",
        "general study"
      ],
      "reasoning": "Requires semantic/contextual understanding to identify abstracts that only mention an indication without any data; exclusions ensure mutual exclusivity."
    }
  ]
}